Navigation Links
EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
Date:8/19/2007

e II trial and another milestone upon the dosing of the first patient in a Phase III trial for any use of the drug.

Myriad also reported data from two completed Phase 1 clinical trials of Azixa in a total of 66 patients, one in patients with refractory solid tumors that may also have had brain metastases and the other in patients with known brain metastases. The trials were designed to explore the safety and pharmacokinetics of Azixa and to find the maximum tolerated dose of the compound. Myriad reported that in the Phase 1 studies, Azixa appeared to have a biological effect on patients' metastases from many different primary tumors, including non-small-cell lung cancer, which is consistent with the mechanism of the drug candidate.

Azixa is one of two compounds in clinical trials discovered through EpiCept's Anti-cancer Screening Apoptosis Program (ASAP). EPC2407, a novel small molecule vascular disruption agent and apoptosis inducer for the treatment of cancer patients with advanced, solid tumors and lymphomas, is currently in Phase I clinical development by EpiCept. In July 2007, EpiCept announced the acceleration of the Phase I clinical trial, with results expected later this year. EpiCept expects to initiate a second Phase I efficacy trial for EPC2407 as a combination therapy in patients with well vascularized solid tumors and intends to choose multiple tumor targets for the compound's Phase II trials as the clinical profile from the ongoing monotherapy trial emerges.

About EpiCept's ASAP Technology

Cancer cells often exhibit unchecked growth caused by the disabling or absence of the natural process of programmed cell death, which is called apoptosis. Apoptosis is normally triggered to destroy a cell from within when it outlives its purpose or it is seriously damaged. One of the most promising approaches in the fight against cancer is to selectively induce apoptosis in cancer cells, thereby checking, and perhaps reversing, the improper ce
'/>"/>

SOURCE EpiCept Corporation

Copyright©2007 PR Newswire.

Page: 1 2 3 4 5

Related biology technology :

1. TomoTherapy reports 86% revenue jump, $131M net loss in Q1
2. Sonic Foundry reports GAAP loss as Q2 revenues rise
3. Fiserv reports $113.5 million in Q1 profit
4. Third Wave reports net loss of $18.9M for 2006
5. Musicnotes reports 45 percent growth in 2006
6. Sonic Foundry reports net loss, higher revenue
7. Sonic Foundry reports first cash-positive quarter
8. Merge Healthcare reports $10.8M net loss in Q3
9. Third Wave reports $5.2M third quarter loss
10. Merge Healthcare appoints new CEO, reports $215 million Q2 loss
11. Merge files financial reports by market opening
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2015)... VANCOUVER , Aug. 28, 2015 /PRNewswire/ - ... clinical stage regenerative medicine company focused on the ... results for the quarter ended June 30, 2015, ... statements and management report are available at ... www.replicel.com . "RepliCel expects to ...
(Date:8/27/2015)... 2015  Neogen Corporation (NASDAQ: NEOG ) announced ... United Kingdom -based Lab M Holdings, a ... diagnostic systems. Lab M was founded ... of microbial testing and diagnostic products for the global ... currently sells into more than 70 countries worldwide, and ...
(Date:8/27/2015)... 2015 HUYA Bioscience International (HUYA) today announced the ... Society of HTLV-1, held this week at the University ... the Society is to promote research on HTLV-1 and ... technology and research related to these fields to advance ... is proud to support this prestigious conference," said ...
(Date:8/27/2015)... ... August 27, 2015 , ... Proove Biosciences, ... data on the relationship of genetics and hypertension at the International Academy ... in Vancouver, British Columbia, Canada. The event, which boasts an extensive overview of ...
Breaking Biology Technology:RepliCel Reports Second Quarter 2015 Financial Results 2RepliCel Reports Second Quarter 2015 Financial Results 3RepliCel Reports Second Quarter 2015 Financial Results 4RepliCel Reports Second Quarter 2015 Financial Results 5Neogen acquires U.K.-based Lab M Holdings 2HUYA Bioscience International Sponsors Japan Society Of HTLV-1 Annual Meeting 2HUYA Bioscience International Sponsors Japan Society Of HTLV-1 Annual Meeting 3HUYA Bioscience International Sponsors Japan Society Of HTLV-1 Annual Meeting 4Proove Biosciences Presents Ground-Breaking Data on Genetics and Heart Disease at 20th World Congress on Heart Disease 2Proove Biosciences Presents Ground-Breaking Data on Genetics and Heart Disease at 20th World Congress on Heart Disease 3
... Mich., Feb. 5 Energy,Conversion Devices, Inc. (ECD) (Nasdaq: ... United Solar Ovonic LLC and United Solar Ovonic,Corporation, have ... aggregate commitment of up to $55 million, pursuant to ... Agreement, each with,JPMorgan Chase Bank, N.A. The new credit ...
... Feb. 5 GeneGo, Inc., the leading,systems biology ... their,licensing agreement with GeneGo and have added additional ... and clinical studies,with global access to MetaCore, MapEditor ... analysis of biological OMICs data,featuring a comprehensive collection ...
... 5 DiObex, Inc., a privately held,biotechnology company focused ... today that CEO David Cory will deliver a,corporate presentation ... Biotechnology and Medical Device Conference in New York,New York. ... 6 at,10:20 a.m. at the Grand Hyatt Hotel in ...
Cached Biology Technology:Energy Conversion Devices and United Solar Ovonic Enter Into New $55 Million Secured Credit Facility Agreements 2GSK Extends GeneGo License and Adds New Products 2
(Date:8/10/2015)... Germany , August 10, 2015 ... leader in Eye Tracking Technology for more than two ... Tracking Platform for integration into all consumer display formats. ... for seamless integration of eye tracking into consumer tablets, ... augmented reality smart glasses. Omnivision,s leading sensor technology contributes ...
(Date:8/6/2015)... , Aug. 6, 2015  Today, U.S. ... visit Crossmatch ™ to learn firsthand how ... protect data. Crossmatch is a world leader in ... and expertise are helping federal agencies and commercial ... security.   "The vast majority of ...
(Date:8/6/2015)... Calif. , Aug. 6, 2015 ... developer of human interface solutions, today announced collaboration ... technologies on Windows 10. Microsoft leveraged Synaptics, deep ... the operating system. Through stringent ... are fully certified with Microsoft,s Precision TouchPad (PTP) ...
Breaking Biology News(10 mins):SMI Completes OEM Eye Tracking Platform to Cover All Consumer Displays 2SMI Completes OEM Eye Tracking Platform to Cover All Consumer Displays 3Rep. Honda to Visit Crossmatch in Redwood City 2Synaptics Chosen for Human Interface Co-Development on Windows 10 2
... major infectious disease today. It is estimated that two ... without active symptoms. Nine million new cases of active ... TB is predominantly a lung disease. It is caused ... cells, but it is still not clear how exactly ...
... the flatworm, planaria, offers new clues for understanding ... Institute have discovered how the worm's cells communicate ... scientists have found that gap-junction (microscopic tunnels directly ... This research, led by Dr. Michael Levin, underlies ...
... in ocean-bottom sediments appears in laboratory tests to ... cells, and potentially with less toxicity than current ... November issue of Cancer Cell. , The experimental ... inhibit cancer cells' proteasomes from working effectively. The ...
Cached Biology News:How does Mycobacterium tuberculosis infect the lung? 2New understanding of regeneration gained by Forsyth scientists 2Compound from marine bacteria shows potential as multiple myeloma therapy 2Compound from marine bacteria shows potential as multiple myeloma therapy 3
Peptide-affinity Purified Polyclonal Antibody to Sphingolipid Receptor Edg8/S1P5...
Peptide-affinity Purified Polyclonal Antibody to MAML1 / Mastermind Peptide with sequence VLPTCPMAEFALPR, from N Terminus of the protein sequence according to NP_055572....
DNA sequencing - plasmids or PCR fragments, 3-7 working days service....
LEAF™ Purified anti-human/mouse/rat ICOS...
Biology Products: